MSC transplants found to extend survival by 4 years in ALS: Analysis
Transplants using mesenchymal stromal cells or MSCs — a type of stem cell found in bone marrow — delivered…
Articles by Patricia Valerio, PhD
FDA names RAG-17, targeting ALS gene mutations, an orphan drug
RAG-17, an investigational therapy from Ractigen Therapeutics to treat amyotrophic lateral sclerosis (ALS), has been designated an orphan…
TDP-43 protein levels show promise as ALS biomarker: Review
Levels of the TDP-43 protein in spinal fluid show promise as biomarkers for amyotrophic lateral…
BrainEver, 3P Partner to Move ALS Therapy Into Clinical Trials
BrainEver has joined in a long-term partnership with 3P Biopharmaceuticals to advance in development its lab-made form of…
FOCUS-C9 Clinical Trial Advances; Complete Data Due 1st Half 2023
Note: This story was updated Nov. 30, 2022, to indicate six patients in the Phase 2a part of FOCUS-C9 will…
ALS Society of Canada, Brain Canada Award 4 Early-stage Research Grants
The ALS Society of Canada and Brain Canada are supporting four early-career scientists who are working to advance…
Startup Granted €10M Seed Funding for 1st-in-class Therapy for ALS
FundaMental Pharma, a spin-out preclinical neuroscience company from Heidelberg University, in Germany, has just been launched with €10 million in…